Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (13371)	10/6/2004 10:43:27 PM
From: former_pgs	Respond to of 52153

If Stellar 3 is a big success, the stock could go above $16 given that right now there appears to be considerable skepticism on the street I certainly agree this is a possibility. CTIC is a tough one, in my opinion, because there are very reasonable scenarios for the optimist and the realist following Stellar 3 success. The realist side of me says that approval based on Stellar 3 would bring with it a label restrictive to PS2 patients that could temper sales estimates and enthusiasm, if that's the street's whim. However, many could view the success in Stellar 3 optimistically as a good omen for the other Stellar trials which are also showing a slower than expected event rate. That raises the roof on valuation. You be the judge! :-)